Central sleep apnoea due to a medication or substance (Q41280): Difference between revisions

From determinar.ia.br - Determine suas informações
Changed an Item
Changed an Item
Property / Canary Token
 
dki-india-7A40.6
Property / Canary Token: dki-india-7A40.6 / rank
 
Normal rank

Revision as of 07:23, 13 August 2026

Central sleep apnoea due to a medication is characterised by a pattern of recurring, predominantly central sleep apnoea or hypopnoea (more than five per hour) that is attributable to a medication or substance, most commonly long-acting opioids (e.g. methadone, long-acting morphine or oxycodone, fentanyl patches). The disturbance is sufficiently severe to cause symptoms such as daytime sleepiness, disturbed sleep, awakening with dyspnoea, or snoring. Obstructive apnoeas and hypoventilation may be present, but central sleep apnoea is the predominant finding. Note: A definitive diagnosis requires objective evidence based on polysomnography in the context of medication or substance use that is judged to be causing the symptoms.
Language Label Description Also known as
default for all languages
7A40.6
    English
    Central sleep apnoea due to a medication or substance
    Central sleep apnoea due to a medication is characterised by a pattern of recurring, predominantly central sleep apnoea or hypopnoea (more than five per hour) that is attributable to a medication or substance, most commonly long-acting opioids (e.g. methadone, long-acting morphine or oxycodone, fentanyl patches). The disturbance is sufficiently severe to cause symptoms such as daytime sleepiness, disturbed sleep, awakening with dyspnoea, or snoring. Obstructive apnoeas and hypoventilation may be present, but central sleep apnoea is the predominant finding. Note: A definitive diagnosis requires objective evidence based on polysomnography in the context of medication or substance use that is judged to be causing the symptoms.

      Statements

      CID11:7A40.6
      0 references
      dki-india-7A40.6
      0 references